These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 26100086)

  • 1. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
    Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
    J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
    Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
    Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
    Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
    Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
    Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
    J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic basis of mast cell activation disease - looking through a glass darkly.
    Molderings GJ
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.
    Nwogbo OV; Fang H; Wang W; Xu J; Miranda RN; Bose P; Ok CY; Jorgensen JL; Medeiros LJ; Wang SA
    Am J Clin Pathol; 2024 Jun; 161(6):598-608. PubMed ID: 38372648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical observations in cutan mastocytosis].
    Mihalik N; Hidvégi B; Hársing J; Várkonyi J; Csomor J; Kovalszky I; Marschalkó M; Kárpáti S
    Orv Hetil; 2013 Sep; 154(37):1469-75. PubMed ID: 24016753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of biology and diagnosis of clonal mast cell diseases in adults.
    Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
    Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastocytosis and related disorders.
    Chiu A; Orazi A
    Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17
    Alvarez-Twose I; Matito A; Morgado JM; Sánchez-Muñoz L; Jara-Acevedo M; García-Montero A; Mayado A; Caldas C; Teodósio C; Muñoz-González JI; Mollejo M; Escribano L; Orfao A
    Oncotarget; 2017 Sep; 8(40):68950-68963. PubMed ID: 28978170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis.
    Gebhard J; Horny HP; Kristensen T; Broesby-Olsen S; Zink A; Biedermann T; Brockow K
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1367-1375. PubMed ID: 35412687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.
    Huang L; Wang SA; Konoplev S; Bueso-Ramos CE; Thakral B; Miranda RN; Jabbour E; Medeiros LJ; Kanagal-Shamanna R
    Medicine (Baltimore); 2016 Oct; 95(41):e4934. PubMed ID: 27741105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
    Chan EC; Bai Y; Kirshenbaum AS; Fischer ER; Simakova O; Bandara G; Scott LM; Wisch LB; Cantave D; Carter MC; Lewis JC; Noel P; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
    J Allergy Clin Immunol; 2014 Jul; 134(1):178-87. PubMed ID: 24582309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.